Testosterone therapy for depression: what the TRAVERSE analysis found
A TRAVERSE analysis found modest mood changes in some men with low testosterone, but no significant benefit in its tiny persistent-depressive-disorder subgroup. It does not establish testosterone as depression treatment.
Testosterone therapy is not established as a treatment for depression. In a TRAVERSE trial analysis, mood and energy measures changed modestly in some men with symptomatic low testosterone, while the 49-person subgroup with low-grade persistent depressive disorder showed no statistically significant benefit. That small subgroup was underpowered, so neither a proven depression benefit nor a definitive absence of one follows from it.1
Depression and low testosterone can coexist, but one label should not automatically explain the other. A person seeking care for mood symptoms needs a mood assessment; a person being evaluated for hypogonadism needs the endocrine record described by the Endocrine Society. Our testosterone-clinic questions help organize that record. A commercial “TRT for depression” pitch collapses these two separate decisions.2
Identify the people studied
TRAVERSE enrolled 5,204 men aged 45–80 with symptoms, two fasting testosterone measurements below the study threshold, and established cardiovascular disease or risk factors. It randomized testosterone gel against placebo. This is a particular study population, not a trial of all people who describe themselves as depressed or tired. The depressive-symptom analysis examined several groups and outcomes rather than one universal depression-treatment endpoint.1
In the broader population and a group with elevated PHQ-9 scores, investigators reported small average mood or energy differences. Only 49 participants met the analysis definition of low-grade persistent depressive disorder. The difference in that subgroup was not statistically significant. The finding should be read with both facts in view: a tiny sample limits precision, and a broader modest score change is not proof that testosterone treats diagnosed major depressive disorder.1
| Question | What the evidence addresses | What it does not settle |
|---|---|---|
| Do some trial participants report mood changes? | Yes, modest average differences in selected analyses | A predictable response for an individual |
| Was persistent depressive disorder treated effectively? | No significant benefit in a 49-person subgroup | A well-powered definitive depression trial |
| Is depression alone a hypogonadism diagnosis? | No; the guideline requires symptoms plus consistently low measured levels | A shortcut from one mood complaint to TRT |
A consultation has two parallel records
For a testosterone discussion, ask which symptoms and repeated measurements establish the proposed diagnosis, what alternative explanations were considered, and which outcome the practice expects to follow. For a depression concern, ask how the clinician plans to assess it and coordinate appropriate mental-health care. Testosterone should not become a substitute for a separate mood evaluation simply because the symptom lists overlap.
The Vitality Trial article answers a different question about fatigue and energy, and should not be cited as proof of depression treatment. The menopause hormone therapy and depression article applies to a different population and treatment. Compare hormone-therapy services if the goal is an endocrine consultation, then ask the practice to state its diagnostic basis and the outcome it can realistically monitor.
What the symptom-score subgroup can and cannot establish
The analysis considered participants with elevated scores on a symptom questionnaire as well as the full trial cohort. A questionnaire cutoff is useful for a research analysis, but it is not the same as a clinician establishing a particular depressive disorder. Nor is a modest change in an average score the same as remission, restored function, or a treatment recommendation for an individual. The 49-person persistent-depressive-disorder subgroup came closest to a specific depression question, yet its small size means the confidence around the effect is wide.1
TRAVERSE was designed around testosterone replacement in men who met low-testosterone entry criteria, not as a head-to-head comparison with established depression care. A man with a depressive condition but normal testosterone was not the target population. A clinic should therefore avoid using this analysis as a shortcut to hormone prescribing whenever someone reports low mood. The study is most useful for setting expectations when a genuine hypogonadism assessment is already underway.12
Keep outcomes visible over time
An evidence-aware plan names the treatment goal at the start. Is the clinician addressing measured testosterone deficiency, sexual symptoms, energy, or mood? If mood is discussed, how is it being assessed separately, and who manages that care? Without such a record, a change in one symptom may be credited to testosterone while other causes or concurrent treatments are ignored.
The Endocrine Society source anchors diagnosis to symptoms and consistently low measured levels, not to one unspecific complaint. A practice that can explain those criteria and coordinate another clinician for mood concerns gives a reader a better decision framework than “TRT boosts mood” marketing.2
Sources
- PubMed. Depressive symptoms and testosterone replacement in TRAVERSE. Randomized trial analysis reports modest mood findings and an underpowered 49-person persistent-depressive-disorder subgroup without significant benefit. Accessed .
- Endocrine Society. Endocrine Society 2018 press release on testosterone prescribing recommendations. The society's 2018 press release summarizes its guideline's diagnostic approach: symptoms plus consistently low measured testosterone, not depression alone. Accessed .